Why Study Third-, Fourth-, Fifth-,...Line Chemotherapy of Ovarian Cancer?

Author： Markman M.  

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.83, Iss.3, 2001-12, pp. : 449-450

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer

By                          

Oncology Letters, Vol. 2, Iss. 6, 2011-01 ,pp. : 1253-1256

Spandidos Publications

Access to resources Recommend Favorite

First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: A Phase I Study

By Sehouli J.   Stengel D.   Elling D.   Ortmann O.   Blohmer J.   Riess H.   Lichtenegger W.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 321-326

Academic Press

Access to resources Recommend Favorite

Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer

By Shim Hyun  

Gastric Cancer, Vol. 14, Iss. 3, 2011-08 ,pp. : 249-256

Springer Publishing Company

Access to resources Recommend Favorite

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

By        

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1140-1148

Spandidos Publications

Access to resources Recommend Favorite

Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite